MedTrace Logo

JT001 (VV116) for the Early Treatment of COVID-19

NCT05242042 · Status: TERMINATED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 381

Last updated 2023-09-22

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy, safety and pharmacokinetics of JT001 (VV116) for the early Treatment of Coronavirus Disease 2019 (COVID-19) in participants with mild to moderate COVID-19, at high risk for progression to severe COVID-19, including death.

Conditions

  • Mild to Moderate COVID-19

Interventions

DRUG

JT001

JT001 administered orally in tablet form every 12 hours for 5 days (10 doses total)

DRUG

Placebo

Placebo matching JT001 administered orally in tablet form every 12 hours for 5 days (10 doses total)

Sponsors & Collaborators

  • Sponsor GmbH

    collaborator OTHER

  • Shanghai JunTop Biosciences Co., LTD

    lead INDUSTRY

Principal Investigators

  • Juan Ma, Medical Director · Shanghai JunTop Biosciences Co., LTD

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-28
Primary Completion
2023-03-23
Completion
2023-03-23

Countries

  • China
  • Hong Kong

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05242042 on ClinicalTrials.gov